Cargando…

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database

INTRODUCTION: The prevalence and detailed biomarkers’ characteristic of rapidly progressive Alzheimer's disease (rpAD) remain incompletely understood. METHODS: A total of 312 mild AD patients from the Alzheimer's Disease Neuroimaging Initiative database were chosen and dichotomized into rp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ba, Maowen, Li, Xiaofeng, Ng, Kok Pin, Pascoal, Tharick A., Mathotaarachchi, Sulantha, Rosa-Neto, Pedro, Gauthier, Serge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651370/ https://www.ncbi.nlm.nih.gov/pubmed/29067322 http://dx.doi.org/10.1016/j.trci.2016.12.005

Ejemplares similares

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease
por: Ng, Kok Pin, et al.
Publicado: (2017)

Characterizing biomarker features of cognitively normal individuals with ventriculomegaly
por: Li, Xiaofeng, et al.
Publicado: (2017)

Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease
por: Ng, Kok Pin, et al.
Publicado: (2021)

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
por: Ba, Maowen, et al.
Publicado: (2016)

Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment
por: Gauthier, Serge, et al.
Publicado: (2018)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem
por: Benedet, Andréa L., et al.
Publicado: (2018)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images
por: Sharafi, Sayed Mehran, et al.
Publicado: (2019)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
por: Therriault, Joseph, et al.
Publicado: (2018)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Imaging Alzheimer's disease pathophysiology with PET
por: Schilling, Lucas Porcello, et al.
Publicado: (2016)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Clusters of male and female Alzheimer’s disease patients in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
por: Gamberger, Dragan, et al.
Publicado: (2016)

Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic
por: Kang, Min Su, et al.
Publicado: (2021)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Iwata, Atsushi, et al.
Publicado: (2018)

The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
por: Macedo, Arthur C., et al.
Publicado: (2023)

Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals
por: Ng, Kok Pin, et al.
Publicado: (2021)

VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis
por: Mathotaarachchi, Sulantha, et al.
Publicado: (2016)

Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
por: Fernández Arias, Jaime, et al.
Publicado: (2023)

Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
por: Ng, Kok Pin, et al.
Publicado: (2017)

In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
por: Savard, Melissa, et al.
Publicado: (2022)

Q & A: The Alzheimer's disease neuroimaging initiative
por: Aisen, Paul S
Publicado: (2011)

Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum
por: Ng, Kok Pin, et al.
Publicado: (2022)

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
por: Pascoal, T A, et al.
Publicado: (2017)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease
por: Tedeschi Dauar, Marina, et al.
Publicado: (2023)

In vivo tau staging in Alzheimer’s disease
por: Therriault, Joseph, et al.
Publicado: (2022)

Prevention strategies for Alzheimer’s disease
por: Gauthier, Serge, et al.
Publicado: (2012)

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rss0urrkhi2b49nn0n5vsq7bv8